Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work that has contributed so greatly to the success of the SBIR program.” Privo would like to congratulate it’s team for their hard work and dedication to the company. On January 10, 2017, Privo’s CEO and Founder, Dr. Manijeh Goldberg, received the honor at the White House during a special awards ceremony.

Go to article
January 10, 2017

Share this post

Author

Related Posts

25Feb

Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors

Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more

27Aug

Privo Technologies Receives $4.5M Funding from National Cancer Institute for Phase 3 Clinical Trial of Innovative Oral Cancer Treatment

  Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support... read more

06Jun

BIO International Convention

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

04Feb

Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

07Sep

FDA Grants $2 million award to Privo Technologies to expedite its clinical trial

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

02Dec

Privo Technologies, Inc. Receives IRB Approval for PRV211- Intraoperative Chemotherapy Treatment for Solid Tumors

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

07Dec

Privo Technologies, Inc. To Attend Biotech Showcase January 17 to January 19, 2022

Peabody, MA-- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy on... read more

09Sep

Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more

19Aug

Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

01Mar

Privo receives a $2M Award from the National Institute of Dental and Craniofacial Research (NIDCR)

Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

Contact Us
close slider

Contact Us